DURYSTA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Durysta, and what generic alternatives are available?
Durysta is a drug marketed by Abbvie and is included in one NDA. There are nine patents protecting this drug.
This drug has one hundred and seventy-seven patent family members in thirty-three countries.
The generic ingredient in DURYSTA is bimatoprost. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Durysta
A generic version of DURYSTA was approved as bimatoprost by APOTEX on December 1st, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DURYSTA?
- What are the global sales for DURYSTA?
- What is Average Wholesale Price for DURYSTA?
Summary for DURYSTA
| International Patents: | 177 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 74 |
| Patent Applications: | 4,457 |
| Drug Prices: | Drug price information for DURYSTA |
| What excipients (inactive ingredients) are in DURYSTA? | DURYSTA excipients list |
| DailyMed Link: | DURYSTA at DailyMed |
Pharmacology for DURYSTA
| Drug Class | Prostaglandin Analog |
US Patents and Regulatory Information for DURYSTA
DURYSTA is protected by nine US patents.
Patents protecting DURYSTA
Hypotensive lipid-containing biodegradable intraocular implants and related implants
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
Processes for making cyclic lipid implants for intraocular use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Hypotensive lipid-containing biodegradable intraocular implants and related methods
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Hypotensive lipid-containing biodegradable intraocular implants and related methods
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Intraocular pressure reduction with intracameral bimatoprost implants
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
Processes for making cyclic lipid implants for intraocular use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Prostamide-containing intraocular implants and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Prostamide-containing intraocular implants and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Abbvie | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Abbvie | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DURYSTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for DURYSTA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| AbbVie Deutschland GmbH & Co. KG | Lumigan | bimatoprost | EMEA/H/C/000391 Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)., |
Authorised | no | no | no | 2002-03-08 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for DURYSTA
See the table below for patents covering DURYSTA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2010513555 | ⤷ Sign Up | |
| Spain | 2707801 | ⤷ Sign Up | |
| Australia | 2005244203 | Biodegradable intraocular implants containing prostamides | ⤷ Sign Up |
| Denmark | 3205333 | ⤷ Sign Up | |
| Poland | 3308769 | ⤷ Sign Up | |
| South Korea | 20070004925 | BIODEGRADABLE INTRAOCULAR IMPLANTS CONTAINING PROSTAMIDES | ⤷ Sign Up |
| Chile | 2012001339 | Forma cristalina ii de 7-[3,5-dihidroxi-2-(3-hidroxi-5-fenil-pent-1-enil)-ciclopentil]-n-etil-hept-5-enamida (bimatoprost); método de conversion de la forma cristalina i del compuesto a la forma cristalina ii; composición farmacéutica; y su uso para tratar hipertensión ocular y glaucoma. | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DURYSTA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0660716 | C300099 | Netherlands | ⤷ Sign Up | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308 |
| 0660716 | SPC/GB02/035 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308 |
| 0660716 | 02C0033 | France | ⤷ Sign Up | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
